Rhabdomyolysis after lung transplantation

Malouf, M.A.; Bicknell, M.; Glanville, A.R.

doi:10.1111/j.1445-5994.1997.tb00938.x

Search citation statements

Order By: Relevance

Paper Sections

Select...

Recommendations For Prophylaxis For Invasive Aspergillosis1

Design Issues Concerning Invasive Aspergillosis In Liver Tra1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2000

2004

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be noted that itraconazole will increase cyclosporine or tacrolimus levels by 35%-50% [76]. Other drug interactions during itraconazole therapy for transplant recipients should also be borne in mind [77]. For example, concurrent use of cyclosporine, simvastatin, and itraconazole has been associated with simvastatin-induced rhabdomyolysis in a lung transplant recipient [77].…”

Section: Recommendations For Prophylaxis For Invasive Aspergillosismentioning

confidence: 99%

Antifungal Prophylaxis for Solid Organ Transplant Recipients: Seeking Clarity Amidst Controversy

Singh

2000

Clinical Infectious Diseases

131

View full text Add to dashboard Cite

Section: Recommendations For Prophylaxis For Invasive Aspergillosismentioning

confidence: 99%

Antifungal Prophylaxis for Solid Organ Transplant Recipients: Seeking Clarity Amidst Controversy

Singh

2000

Clinical Infectious Diseases

131

View full text Add to dashboard Cite

“…The azoles also have significant interaction with the statins. Concurrent use of cyclosporine, simvastatin, and itraconazole was associated with rhabdomyolysis in a transplant recipient [24].…”

Section: Design Issues Concerning Invasive Aspergillosis In Liver Tramentioning

confidence: 99%

Antifungal Prophylaxis in Solid-Organ Transplant Recipients: Considerations for Clinical Trial Design

Singh

2004

Clinical Infectious Diseases

View full text Add to dashboard Cite

Background. There are several key issues regarding clinical trial design for antifungal prophylaxis in organ transplant recipients.Methods. The existing and emerging data on the epidemiology and risk factors for invasive mycoses in organ transplant recipients formed the basis for discerning the subgroups that may be targeted for prophylaxis, the unique end points to be considered, and the attributes of currently available drugs that may be suitable candidates for antifungal prophylaxis.Results. Epidemiological characteristics of invasive mycoses in organ transplant recipients have evolved sufficiently to warrant thoughtful reconsideration of the subsets of patients and the fungal pathogens to be targeted for antifungal prophylactic trials in the current era. Safety and tolerability of antifungal agents and outcome stratified by severity of illness are important end points given the potential for drug interactions with immunosuppressive agents and the fact that a beneficial effect of prophylaxis on outcome has been difficult to document in organ transplant recipients.Conclusions. Clinical trial design for antifungal prophylaxis must carefully consider the unique issues pertaining to the selection of patients most likely to benefit, as well as the tolerability and drug interactions of antifungal agents in organ transplant recipients.

show abstract

Rhabdomyolysis after lung transplantation

Cited by 2 publications

References 4 publications

Antifungal Prophylaxis for Solid Organ Transplant Recipients: Seeking Clarity Amidst Controversy

Antifungal Prophylaxis for Solid Organ Transplant Recipients: Seeking Clarity Amidst Controversy

Antifungal Prophylaxis in Solid-Organ Transplant Recipients: Considerations for Clinical Trial Design

Contact Info

Product

Resources

About